Reuters logo
a year ago
BRIEF-Aviragen delays further enrollment phase 2A trial for drug to treat RSV infections
May 26, 2016 / 8:51 PM / a year ago

BRIEF-Aviragen delays further enrollment phase 2A trial for drug to treat RSV infections

May 26 (Reuters) - Aviragen Therapeutics Inc

* Voluntarily decided to delay further enrollment in phase 2a trial of bta585 for treatment of RSV infections being conducted in U.K

* Decision emanated from a lab report from 1 subject showing an increase of a cardiac enzyme level coupled with transient ECG changes

* Received verbal communication from FDA that IND for BTA585 has been placed on clinical hold

* There are currently no trials of BTA585 being conducted under IND.

* More specific written information from FDA concerning clinical hold is expected within 30 days

* Reached out to medicines and healthcare products regulatory agency to discuss this event

* Aviragen Therapeutics provides update on phase 2a trial of bta585 for the treatment of RSV infections Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below